Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023. In the quarter to June 2026, revenue fell 57.1%, EPS grew 71.9%, free cash flow grew 25.3% and total debt rose 1.54%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow GUTS
Fractyl Health, Inc. (GUTS) P/E ratio
Fractyl Health, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GUTS Fractyl Health, Inc. | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| RNXT RenovoRx, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)